Cargando…

Extracorporeal carbon dioxide removal for acute hypercapnic exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a common cause of chronic respiratory failure and its course is punctuated by a series of acute exacerbations which commonly lead to hospital admission. Exacerbations are managed through the application of non-invasive ventilation and, when...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrett, Nicholas A., Kostakou, Eirini, Hart, Nicholas, Douiri, Abdel, Camporota, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664508/
https://www.ncbi.nlm.nih.gov/pubmed/31362776
http://dx.doi.org/10.1186/s13063-019-3548-4
_version_ 1783439897725501440
author Barrett, Nicholas A.
Kostakou, Eirini
Hart, Nicholas
Douiri, Abdel
Camporota, Luigi
author_facet Barrett, Nicholas A.
Kostakou, Eirini
Hart, Nicholas
Douiri, Abdel
Camporota, Luigi
author_sort Barrett, Nicholas A.
collection PubMed
description BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a common cause of chronic respiratory failure and its course is punctuated by a series of acute exacerbations which commonly lead to hospital admission. Exacerbations are managed through the application of non-invasive ventilation and, when this fails, tracheal intubation and mechanical ventilation. The need for mechanical ventilation significantly increases the risk of death. An alternative therapy, extracorporeal carbon dioxide removal (ECCO(2)R), has been shown to be efficacious in removing carbon dioxide from the blood; however, its impact on respiratory physiology and patient outcomes has not been explored. METHODS/DESIGN: A randomised controlled open label trial of patients (12 in each arm) with acute exacerbations of COPD at risk of failing conventional therapy (NIV) randomised to either remaining on NIV or having ECCO(2)R added to NIV with a primary endpoint of time to cessation of NIV. The change in respiratory physiology following the application of ECCO(2)R and/or NIV will be measured using electrical impedance tomography, oesophageal pressure and parasternal electromyography. Additional outcomes, including patient tolerance, outcomes, need for readmission, changes in blood gases and biochemistry and procedural complications, will be measured. Physiological changes will be compared within one patient over time and between the two groups. Healthcare costs in the UK system will also be compared between the two groups. DISCUSSION: COPD is a common disease and exacerbations are a leading cause of hospital admission in the UK and worldwide, with a sizeable mortality. The management of patients with COPD consumes significant hospital and financial resources. This study seeks to understand the feasibility of a novel approach to the management of patients with acute exacerbations of COPD as well as to understand the underlying physiological changes to explain why the approach does or does not assist this patient cohort. Detailed respiratory physiology has not been previously undertaken using this technique and there are no other randomised controlled trials currently in the literature. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02086084. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-019-3548-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6664508
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66645082019-08-05 Extracorporeal carbon dioxide removal for acute hypercapnic exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial Barrett, Nicholas A. Kostakou, Eirini Hart, Nicholas Douiri, Abdel Camporota, Luigi Trials Study Protocol BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a common cause of chronic respiratory failure and its course is punctuated by a series of acute exacerbations which commonly lead to hospital admission. Exacerbations are managed through the application of non-invasive ventilation and, when this fails, tracheal intubation and mechanical ventilation. The need for mechanical ventilation significantly increases the risk of death. An alternative therapy, extracorporeal carbon dioxide removal (ECCO(2)R), has been shown to be efficacious in removing carbon dioxide from the blood; however, its impact on respiratory physiology and patient outcomes has not been explored. METHODS/DESIGN: A randomised controlled open label trial of patients (12 in each arm) with acute exacerbations of COPD at risk of failing conventional therapy (NIV) randomised to either remaining on NIV or having ECCO(2)R added to NIV with a primary endpoint of time to cessation of NIV. The change in respiratory physiology following the application of ECCO(2)R and/or NIV will be measured using electrical impedance tomography, oesophageal pressure and parasternal electromyography. Additional outcomes, including patient tolerance, outcomes, need for readmission, changes in blood gases and biochemistry and procedural complications, will be measured. Physiological changes will be compared within one patient over time and between the two groups. Healthcare costs in the UK system will also be compared between the two groups. DISCUSSION: COPD is a common disease and exacerbations are a leading cause of hospital admission in the UK and worldwide, with a sizeable mortality. The management of patients with COPD consumes significant hospital and financial resources. This study seeks to understand the feasibility of a novel approach to the management of patients with acute exacerbations of COPD as well as to understand the underlying physiological changes to explain why the approach does or does not assist this patient cohort. Detailed respiratory physiology has not been previously undertaken using this technique and there are no other randomised controlled trials currently in the literature. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02086084. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-019-3548-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-30 /pmc/articles/PMC6664508/ /pubmed/31362776 http://dx.doi.org/10.1186/s13063-019-3548-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Barrett, Nicholas A.
Kostakou, Eirini
Hart, Nicholas
Douiri, Abdel
Camporota, Luigi
Extracorporeal carbon dioxide removal for acute hypercapnic exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial
title Extracorporeal carbon dioxide removal for acute hypercapnic exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial
title_full Extracorporeal carbon dioxide removal for acute hypercapnic exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial
title_fullStr Extracorporeal carbon dioxide removal for acute hypercapnic exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial
title_full_unstemmed Extracorporeal carbon dioxide removal for acute hypercapnic exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial
title_short Extracorporeal carbon dioxide removal for acute hypercapnic exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial
title_sort extracorporeal carbon dioxide removal for acute hypercapnic exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664508/
https://www.ncbi.nlm.nih.gov/pubmed/31362776
http://dx.doi.org/10.1186/s13063-019-3548-4
work_keys_str_mv AT barrettnicholasa extracorporealcarbondioxideremovalforacutehypercapnicexacerbationsofchronicobstructivepulmonarydiseasestudyprotocolforarandomisedcontrolledtrial
AT kostakoueirini extracorporealcarbondioxideremovalforacutehypercapnicexacerbationsofchronicobstructivepulmonarydiseasestudyprotocolforarandomisedcontrolledtrial
AT hartnicholas extracorporealcarbondioxideremovalforacutehypercapnicexacerbationsofchronicobstructivepulmonarydiseasestudyprotocolforarandomisedcontrolledtrial
AT douiriabdel extracorporealcarbondioxideremovalforacutehypercapnicexacerbationsofchronicobstructivepulmonarydiseasestudyprotocolforarandomisedcontrolledtrial
AT camporotaluigi extracorporealcarbondioxideremovalforacutehypercapnicexacerbationsofchronicobstructivepulmonarydiseasestudyprotocolforarandomisedcontrolledtrial